LLMab has superior half life, doesn't get broken down via liver / via cyp450 pathway (low toxicity risk), and binds to other of the CCR5 loops, not the active site.. it's a one-in-a-billion or trillion molecule. Cost will eventually come down but since a large part of that will go to scaling up production, it's well worth it.